Hannah was 11 when she was diagnosed with acute lymphoblastic leukemia (ALL). Four years, two relapses and a 53-day hospital stay later, she is back in school.
|Articles|August 26, 2015
Susan Thornton on Bridging the Knowledge Gap Between Researchers and Patients
Susan Thornton discusses her story and her efforts to bridge the knowledge gap between researchers and patients.
Advertisement
Susan Thornton, CEO, Cutaneous Lymphoma Foundation, discusses her efforts to bridge the knowledge gap between researchers and patients.
Advertisement
Related to this article
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Dr. Doured Daghistani explains how pediatric oncology is shifting toward reducing long-term side effects as childhood cancer survival rates rise.
Cancer can change, hide from the immune system and escape treatment, making effective therapy about more than targeting cancer cells alone.
Advertisement
Advertisement
Trending on CURE
1
Enhertu in HER2-Mutant Lung Cancer: The First Year, Side Effects and Sequencing
2
Top 3 Takeaways From WCLC 2026 That Patients Should Know
3
A Gift from the Sea
4
Childhood Leukemia Survivor Shares Her Experience With ALL, Relapse and CAR-T
5